semaglutide mcas Not all GLP-1s work the same way for MCAS. Most patients do better on Tirzepatide, the dual incretin with both GLP-1 and GIP receptor agonists. But some mast cells just respond better GI and Hepatology News -

Survodutide : A dual GLP-1/glucagon receptor agonist that achieved 14.9% weight loss at 46 weeks in a phase 2 trial

It controls blood sugar, cuts calorie intake, and uses energy well

Key results: Mean weight loss: 20.2% with tirzepatide vs

Electrolytes: the non-negotiable addition Both the ketogenic diet and semaglutide create electrolyte management challenges that compound when combined

Hviid, A

Dose Escalation Schedule Semaglutide dosage starts low and follows a gradual dose escalation to improve tolerance, minimize gastrointestinal side effects like nausea, and optimize effectiveness for type 2 diabetes control or weight loss goals